Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transnasal Sphenopalatine Ganglia Block for Pediatric Chronic Migraines
NCT04466826Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2021
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bupivacaine in chronic migraine (CM), sponsored by Washington University School of Medicine. Planned start Jan 2021; status: withdrawn.
02
Drugs
bupivacaine
03
Conditions
chronic migraine (CM)
Beyond the preview
Go deeper on NCT04466826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04466826.